Search

Your search keyword '"Rea, Delphine"' showing total 864 results
Start Over Author "Rea, Delphine"
864 results on '"Rea, Delphine"'

2. Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials.

Author

Jabbour, Elias, Apperley, Jane, Cortes, Jorge, Rea, Delphine, Deininger, Michael, Abruzzese, Elisabetta, Chuah, Charles, DeAngelo, Daniel, Hochhaus, Andreas, Lipton, Jeffrey, Mauro, Michael, Nicolini, Franck, Pinilla-Ibarz, Javier, Rosti, Gianantonio, Rousselot, Philippe, Talpaz, Moshe, Vorog, Alexander, Ren, Xiaowei, Kantarjian, Hagop, and Shah, Neil Pravin

Subjects
Humans, Drug Resistance, Neoplasm, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Imidazoles, Pyridazines, Fusion Proteins, bcr-abl, Protein Kinase Inhibitors, Antineoplastic Agents
Abstract

Ponatinib, the only approved all known-BCR::ABL1 inhibitor, is a third-generation tyrosine-kinase inhibitor (TKI) designed to inhibit BCR::ABL1 with or without any single resistance mutation, including T315I, and induced robust and durable responses at 45 mg/day in patients with CP-CML resistant to second-generation TKIs in the PACE trial. However, cardiovascular toxicities, including arterial occlusive events (AOEs), have emerged as treatment-related AEs within this class of TKIs. The OPTIC trial evaluated the efficacy and safety of ponatinib using a novel, response-based, dose-reduction strategy in patients with CP-CML whose disease is resistant to ≥2 TKIs or who harbor T315I. To assess the dose-response relationship and the effect on the safety of ponatinib, we examined the outcomes of patients with CP-CML enrolled in PACE and OPTIC who received 45 mg/day of ponatinib. A propensity score analysis was used to evaluate AOEs across both trials. Survival rates and median time to achieve ≤1% BCR::ABL1IS in OPTIC were similar or better than in PACE. The outcomes of patients with T315I mutations were robust in both trials. Patients in OPTIC had a lower exposure-adjusted incidence of AOEs compared with those in PACE. This analysis demonstrates that response-based dosing for ponatinib improves treatment tolerance and mitigates cardiovascular risk.

Published
2024

3. Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results

Author

Cortes, Jorge E., Sasaki, Koji, Kim, Dong-Wook, Hughes, Timothy P., Etienne, Gabriel, Mauro, Michael J., Hochhaus, Andreas, Lang, Fabian, Heinrich, Michael C., Breccia, Massimo, Deininger, Michael, Goh, Yeow Tee, Janssen, Jeroen J.W.M., Talpaz, Moshe, de Soria, Valle Gomez Garcia, le Coutre, Philipp, DeAngelo, Daniel J., Damon, Andrea, Cacciatore, Silvia, Polydoros, Fotis, Agrawal, Nithya, and Rea, Delphine

Published
2024
Full Text
View/download PDF

4. Treatment‐free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: Final 5‐year analysis of DASFREE

Author

Shah, Neil P, García‐Gutiérrez, Valentín, Jiménez‐Velasco, Antonio, Larson, Sarah M, Saussele, Susanne, Rea, Delphine, Mahon, François‐Xavier, Levy, Moshe Yair, Gómez‐Casares, María Teresa, Mauro, Michael J, Sy, Oumar, Martin‐Regueira, Patricia, and Lipton, Jeffrey H

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Clinical Research, Rare Diseases, 6.1 Pharmaceuticals, Cancer, Humans, Dasatinib, Protein Kinase Inhibitors, Treatment Outcome, Neoplasm Recurrence, Local, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, chronic phase chronic myeloid leukaemia, dasatinib, deep molecular response, major molecular response, treatment-free remission, Cardiorespiratory Medicine and Haematology, Immunology, Cardiovascular medicine and haematology
Abstract

Patients with chronic myeloid leukaemia in chronic phase (CML-CP) who have a sustained deep molecular response (DMR) are eligible to discontinue treatment and attempt treatment-free remission (TFR). In the DASFREE study (ClinicalTrials.gov; NCT01850004), the 2-year TFR rate after dasatinib discontinuation was 46%; here we present the 5-year update. Patients with a stable DMR after ≥2 years of dasatinib therapy discontinued treatment and were followed for 5 years. At a minimum follow-up of 60 months, in 84 patients discontinuing dasatinib, the 5-year TFR rate was 44% (n = 37). No relapses occurred after month 39 and all evaluable patients who relapsed and restarted dasatinib (n = 46) regained a major molecular response in a median of 1.9 months. The most common adverse event during the off-treatment period was arthralgia (18%, 15/84); a total of 15 withdrawal events were reported in nine patients (11%). At the 5-year final follow-up, almost half of the patients who discontinued dasatinib after a sustained DMR maintained TFR. All evaluable patients who experienced a relapse quickly regained a DMR after restarting dasatinib, demonstrating that dasatinib discontinuation is a viable and potentially long-term option in patients with CML-CP. The safety profile is consistent with the previous report.

Published
2023

5. Chronic myeloid leukemia diagnosed in pregnancy: management and outcome of 87 patients reported to the European LeukemiaNet international registry

Author

Chelysheva, Ekaterina, Apperley, Jane, Turkina, Anna, Yassin, Mohamed A., Rea, Delphine, Nicolini, Franck E., Barraco, Daniela, Kazakbaeva, Khamida, Saliev, Sukhrob, Abulafia, Adi Shacham, Al-Kindi, Salam, Byrne, Jennifer, Robertson, Harry F., Cerrano, Marco, Shmakov, Roman, Polushkina, Evgenia, de Fabritiis, Paolo, Trawinska, Malgorzata Monika, and Abruzzese, Elisabetta

Published
2024
Full Text
View/download PDF

6. Correction: Chronic myeloid leukemia diagnosed in pregnancy: management and outcome of 87 patients reported to the European LeukemiaNet international registry

Author

Chelysheva, Ekaterina, Apperley, Jane, Turkina, Anna, Yassin, Mohamed A., Rea, Delphine, Nicolini, Franck E., Barraco, Daniela, Kazakbaeva, Khamida, Saliev, Sukhrob, Abulafia, Adi Shacham, Al-Kindi, Salam, Byrne, Jennifer, Robertson, Harry F., Cerrano, Marco, Shmakov, Roman, Polushkina, Evgenia, de Fabritiis, Paolo, Trawinska, Malgorzata Monika, and Abruzzese, Elisabetta

Published
2024
Full Text
View/download PDF

7. Correction: Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials

Author

Jabbour, Elias, Apperley, Jane, Cortes, Jorge, Rea, Delphine, Deininger, Michael, Abruzzese, Elisabetta, Chuah, Charles, DeAngelo, Daniel J., Hochhaus, Andreas, Lipton, Jeffrey H., Mauro, Michael, Nicolini, Franck, Pinilla-Ibarz, Javier, Rosti, Gianantonio, Rousselot, Philippe, Shah, Neil P., Talpaz, Moshe, Vorog, Alexander, Ren, Xiaowei, and Kantarjian, Hagop

Published
2024
Full Text
View/download PDF

9. Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results

Author

Mauro, Michael J., Hughes, Timothy P., Kim, Dong-Wook, Rea, Delphine, Cortes, Jorge E., Hochhaus, Andreas, Sasaki, Koji, Breccia, Massimo, Talpaz, Moshe, Ottmann, Oliver, Minami, Hironobu, Goh, Yeow Tee, DeAngelo, Daniel J., Heinrich, Michael C., Gómez-García de Soria, Valle, le Coutre, Philipp, Mahon, Francois-Xavier, Janssen, Jeroen J. W. M., Deininger, Michael, Shanmuganathan, Naranie, Geyer, Mark B., Cacciatore, Silvia, Polydoros, Fotis, Agrawal, Nithya, Hoch, Matthias, and Lang, Fabian

Published
2023
Full Text
View/download PDF

10. First-line second generation tyrosine kinase inhibitors in patients with newly diagnosed accelerated phase chronic myeloid leukemia

Author

Balsat, Marie, Alcazer, Vincent, Etienne, Gabriel, Huguet, Françoise, Berger, Marc, Cayssials, Emilie, Charbonnier, Aude, Escoffre-Barbe, Martine, Johnson-Ansah, Hyacinthe, Legros, Laurence, Roy, Lydia, Delmer, Alain, Ianotto, Jean-Christophe, Orvain, Corentin, Larosa, Fabrice, Meunier, Mathieu, Amé, Shanti, Andreoli, Annalisa, Cony-Makhoul, Pascale, Morisset, Stéphane, Tigaud, Isabelle, Rea, Delphine, and Nicolini, Franck Emmanuel

Published
2023
Full Text
View/download PDF

12. Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia

Author

Hughes, Timothy P, Laneuville, Pierre, Rousselot, Philippe, Snyder, David S, Rea, Delphine, Shah, Neil P, Paar, David, Abruzzese, Elisabetta, Hochhaus, Andreas, Lipton, Jeffrey H, and Cortes, Jorge E

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Orphan Drug, Pediatric Research Initiative, Pediatric, Clinical Trials and Supportive Activities, Hematology, Childhood Leukemia, Pediatric Cancer, Rare Diseases, Clinical Research, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Adult, Dasatinib, Disease-Free Survival, Female, Humans, Incidence, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Male, Middle Aged, Pleural Effusion, Malignant, Risk Factors, Survival Rate, Cardiorespiratory Medicine and Haematology, Immunology, Cardiovascular medicine and haematology
Abstract

Dasatinib, a second-generation BCR-ABL1 tyrosine kinase inhibitor, is approved for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia, both as first-line therapy and after imatinib intolerance or resistance. While generally well tolerated, dasatinib has been associated with a higher risk for pleural effusions. Frequency, risk factors, and outcomes associated with pleural effusion were assessed in two phase 3 trials (DASISION and 034/Dose-optimization) and a pooled population of 11 trials that evaluated patients with chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia treated with dasatinib (including DASISION and 034/Dose-optimization). In this largest assessment of patients across the dasatinib clinical trial program (N=2712), pleural effusion developed in 6-9% of patients at risk annually in DASISION, and in 5-15% of patients at risk annually in 034/Dose-optimization. With a minimum follow up of 5 and 7 years, drug-related pleural effusion occurred in 28% of patients in DASISION and in 33% of patients in 034/Dose-optimization, respectively. A significant risk factor identified for developing pleural effusion by a multivariate analysis was age. We found that overall responses to dasatinib, progression-free survival, and overall survival were similar in patients who developed pleural effusion and in patients who did not. clinicaltrials.gov identifier 00481247; 00123474.

Published
2019

16. European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia : Final Analysis and Novel Prognostic Factors for Treatment-Free Remission

Author

Mahon, Francois-Xavier, Pfirrmann, Markus, Dulucq, Stephanie, Hochhaus, Andreas, Panayiotidis, Panayiotis, Almeida, Antonio, Mayer, Jiri, Hjorth-Hansen, Henrik, Janssen, Jeroen J. W. M., Mustjoki, Satu, Martinez-Lopez, Joaquin, Vestergaard, Hanne, Ehrencrona, Hans, Polakova, Katerina Machova, Olsson-Strömberg, Ulla, Ossenkoppele, Gert, Berger, Marc G., Etienne, Gabriel, Dengler, Jolanta, Bruemmendorf, Tim H., Burchert, Andreas, Rea, Delphine, Rousselot, Philippe, Nicolini, Franck E., Hofmann, Wolf-Karsten, Richter, Johan, Saussele, Susanne, Mahon, Francois-Xavier, Pfirrmann, Markus, Dulucq, Stephanie, Hochhaus, Andreas, Panayiotidis, Panayiotis, Almeida, Antonio, Mayer, Jiri, Hjorth-Hansen, Henrik, Janssen, Jeroen J. W. M., Mustjoki, Satu, Martinez-Lopez, Joaquin, Vestergaard, Hanne, Ehrencrona, Hans, Polakova, Katerina Machova, Olsson-Strömberg, Ulla, Ossenkoppele, Gert, Berger, Marc G., Etienne, Gabriel, Dengler, Jolanta, Bruemmendorf, Tim H., Burchert, Andreas, Rea, Delphine, Rousselot, Philippe, Nicolini, Franck E., Hofmann, Wolf-Karsten, Richter, Johan, and Saussele, Susanne

Abstract

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.The European Stop Kinase Inhibitors (EURO-SKI) study is the largest clinical trial for investigating the cessation of tyrosine kinase inhibitors (TKIs) in patients with chronic myeloid leukemia in stable deep molecular remission (DMR). Among 728 patients, 434 patients (61%; 95% CI, 57 to 64) remained in major molecular response (MMR) at 6 months and 309 patients of 678 (46%; 95% CI, 42 to 49) at 36 months. Duration of TKI treatment and DMR before TKI stop were confirmed as significant factors for the prediction of MMR loss at 6 months. In addition, the type of BCR::ABL1 transcript was identified as a prognostic factor. For late MMR losses after 6 months, TKI treatment duration, percentage of blasts in peripheral blood, and platelet count at diagnosis were significant factors in multivariate analysis. For the entire study period of 36 months, multiple logistic regression models confirmed duration of treatment, blasts, and transcript type as independent factors for MMR maintenance. In addition to the duration of treatment, transcript type as well as blasts in peripheral blood at diagnosis should be considered as important factors to predict treatment-free remission.

Published
2024
Full Text
View/download PDF

19. Kinetics of molecular recurrence after tyrosine kinase inhibitor cessation in chronic phase chronic myelogenous leukaemia patients

Author

Alcazer, Vincent, primary, Morisset, Stéphane, additional, Rea, Delphine, additional, Legros, Laurence, additional, Dulucq, Stéphanie, additional, Hayette, Sandrine, additional, Cayuela, Jean‐Michel, additional, Huguet, Françoise, additional, Mahon, François‐Xavier, additional, Etienne, Gabriel, additional, and Nicolini, Franck E., additional

Published
2024
Full Text
View/download PDF

20. Dasatinib in imatinib‐resistant or ‐intolerant chronic‐phase, chronic myeloid leukemia patients: 7‐year follow‐up of study CA180‐034

Author

Shah, Neil P, Rousselot, Philippe, Schiffer, Charles, Rea, Delphine, Cortes, Jorge E, Milone, Jorge, Mohamed, Hesham, Healey, Diane, Kantarjian, Hagop, Hochhaus, Andreas, and Saglio, Giuseppe

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Clinical Sciences, Oncology and Carcinogenesis, Orphan Drug, Clinical Research, Cancer, Hematology, Rare Diseases, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Antineoplastic Agents, Dasatinib, Disease-Free Survival, Drug Resistance, Neoplasm, Follow-Up Studies, Humans, Imatinib Mesylate, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase, Pancytopenia, Patient Safety, Pleural Effusion, Protein Kinase Inhibitors, Treatment Outcome, Cardiorespiratory Medicine and Haematology, Immunology, Cardiovascular medicine and haematology
Abstract

Dasatinib was approved at 100 mg once daily for imatinib-resistant or -intolerant patients with chronic myeloid leukemia (CML) in chronic phase, based on results of the phase 3 CA180-034 (NCT00123474) study. Here we present the final 7-year analysis of this pivotal study, the longest follow-up to date of any second-generation BCR-ABL1 tyrosine kinase inhibitor (TKI). Patients (n = 670) with imatinib-resistant or -intolerant CML in chronic phase received dasatinib. Nineteen percent of patients continued on study treatment, with a greater proportion in the 100 mg once daily arm remaining on therapy. Seven-year rates for major molecular response (MMR), progression-free survival (PFS), and overall survival (OS) were similar across doses; MMR, PFS, and OS results were 46, 42, and 65% at 100 mg once daily, respectively. Improved PFS and OS rates were reported in patients who achieved BCR-ABL1 ≤10% at 3 and 6 months. No new safety signals were identified. The incidence of drug-related pleural effusion was 28% at 100 mg once daily and 35% at the other three dose groups. Incidence of drug-related pulmonary hypertension and pulmonary arterial hypertension remained low (≤3% across all doses). Arterial ischemic events occurred in ≤4% of patients across all doses. These data support the long-term efficacy and well-established safety profile of dasatinib for patients with imatinib-resistant or -intolerant CML in chronic phase. Am. J. Hematol. 91:869-874, 2016. © 2016 Wiley Periodicals, Inc.

Published
2016

21. Optimisation du bosutinib dans la leucémie myéloïde chronique : recommandations du Fi-LMC (France Intergroupe des leucémies myéloïdes chroniques)

Author

Rea, Delphine, primary, Cayssials, Emilie, additional, Charbonnier, Aude, additional, Coiteux, Valérie, additional, Etienne, Gabriel, additional, Goldwirt, Lauriane, additional, Guerci-Bresler, Agnès, additional, Huguet, Françoise, additional, Legros, Laurence, additional, Roy, Lydia, additional, and Nicolini, Franck Emmanuel, additional

Published
2023
Full Text
View/download PDF

23. BCR::ABL1kinase N-lobe mutants confer moderate to high degrees of resistance to asciminib

Author

Leyte-Vidal, Ariel, Garrido Ruiz, Diego, DeFilippis, RosaAnna, Leske, Inga B., Rea, Delphine, Phan, Stacey, Miller, Kaeli B., Hu, Feifei, Mase, Anjeli, Shan, Yibing, Hantschel, Oliver, Jacobson, Matthew P., and Shah, Neil P.

Abstract

•BCR::ABL1 M244V confers clinical resistance to asciminib; M244V and other kinase N-lobe mutations confer resistance to asciminib in vitro.•Mutations in the BCR::ABL1 kinase domain may impair the durability of response to combinations of asciminib and ATP-competitive TKIs.

Published
2024
Full Text
View/download PDF

24. Treatment-Free Remission after Ponatinib Cessation in Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients. the Ponastop Observational Study

Author

Nicolini, Franck E., primary, Abruzzese, Elisabetta, additional, Roth-Guepin, Gabrielle, additional, Abi-Tayeh, Rami, additional, Alcazer, Vincent, additional, Hayette, Sandrine, additional, Morisset, Stéphane, additional, Huguet, Françoise, additional, Iezza, Miriam, additional, Castagnetti, Fausto, additional, and Rea, Delphine, additional

Published
2023
Full Text
View/download PDF

25. CML-398 Responses With Asciminib Continue to Deepen Over Time in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After ≥2 Prior Tyrosine Kinase Inhibitors (TKIs) in the Phase III ASCEMBL Study

Author

Mauro, Michael, primary, Hochhaus, Andreas, additional, Hughes, Timothy, additional, Rea, Delphine, additional, Boquimpani, Carla, additional, Minami, Yosuke, additional, Apperley, Jane, additional, Garcia-Gutiérrez, Valentin, additional, Kapoor, Shruti, additional, Espurz, Noemi, additional, Dhamal, Vishal, additional, and Cortes, Jorge, additional

Published
2023
Full Text
View/download PDF

26. POSTER: CML-310 Early Cytogenetic or Molecular Landmark Response to Ponatinib Treatment Predicts Outcomes in Heavily Pretreated Patients With Chronic-Phase Chronic Myeloid Leukemia (CP-CML) in PACE: 5-Year Data

Author

Müller, Martin C., primary, Cortes, Jorge, additional, Chuah, Charles, additional, DeAngelo, Daniel J., additional, Deininger, Michael, additional, Guilhot, François, additional, Hughes, Timothy, additional, Nicolini, Franck E., additional, Pinilla-Ibarz, Javier, additional, Rea, Delphine, additional, Rosti, Gianantonio, additional, Shah, Neil P., additional, Talpaz, Moshe, additional, Lu, Vickie, additional, Padukkavidana, Thihan, additional, and Kantarjian, Hagop M., additional

Published
2023
Full Text
View/download PDF

27. POSTER: CML-398 Responses With Asciminib Continue to Deepen Over Time in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After ≥2 Prior Tyrosine Kinase Inhibitors (TKIs) in the Phase III ASCEMBL Study

Author

Mauro, Michael, primary, Hochhaus, Andreas, additional, Hughes, Timothy, additional, Rea, Delphine, additional, Boquimpani, Carla, additional, Minami, Yosuke, additional, Apperley, Jane, additional, Garcia-Gutiérrez, Valentin, additional, Kapoor, Shruti, additional, Espurz, Noemi, additional, Dhamal, Vishal, additional, and Cortes, Jorge, additional

Published
2023
Full Text
View/download PDF

28. CML-310 Early Cytogenetic or Molecular Landmark Response to Ponatinib Treatment Predicts Outcomes in Heavily Pretreated Patients With Chronic-Phase Chronic Myeloid Leukemia (CP-CML) in PACE: 5-Year Data

Author

Müller, Martin C., primary, Cortes, Jorge, additional, Chuah, Charles, additional, DeAngelo, Daniel J., additional, Deininger, Michael, additional, Guilhot, François, additional, Hughes, Timothy, additional, Nicolini, Franck E., additional, Pinilla-Ibarz, Javier, additional, Rea, Delphine, additional, Rosti, Gianantonio, additional, Shah, Neil P., additional, Talpaz, Moshe, additional, Lu, Vickie, additional, Padukkavidana, Thihan, additional, and Kantarjian, Hagop M., additional

Published
2023
Full Text
View/download PDF

29. CML-466 Asciminib Provides Durable Molecular Responses in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With the T315I Mutation: Updated Efficacy and Safety Data From a Phase I Trial

Author

Hughes, Timothy P., Cortes, Jorge E., Réa, Delphine, Mauro, Michael J., Hochhaus, Andreas, Kim, Dong-Wook, Sasaki, Koji, Lang, Fabian, Heinrich, Michael C., Breccia, Massimo, Deininger, Michael, Goh, Yeow-Tee, Janssen, Jeroen J. W.M, Talpaz, Moshe, Coutre, Philipp le, Kapoor, Shruti, Cacciatore, Silvia, Polydoros, Fotis, Agrawal, Nithya, and Mahon, Francois-Xavier

Published
2022
Full Text
View/download PDF

30. CML-395 Efficacy and Safety Results From ASCEMBL, a Phase III Study of Asciminib vs. Bosutinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After ≥2 Prior Tyrosine Kinase Inhibitors (TKIs): Week 96 Update

Author

Réa, Delphine, Hochhaus, Andreas, Mauro, Michael J., Minami, Yosuke, Lomaia, Elza, Voloshin, Sergey, Turkina, Anna, Kim, Dong-Wook, Apperley, Jane F., Cortes, Jorge E., Abdo, Andre, Fogliatto, Laura Marie, Kim, Dennis Dong Hwan, Coutre, Philipp le, Saussele, Susanne, Annunziata, Mario, Hughes, Timothy P., Chaudhri, Naeem, Chee, Lynette, García-Gutiérrez, Valentin, Sasaki, Koji, Kapoor, Shruti, Allepuz, Alex, Quenet, Sara, Bédoucha, Véronique, and Boquimpani, Carla

Published
2022
Full Text
View/download PDF

31. CML-046 Dose Modification Dynamics of Ponatinib in Patients With Chronic-Phase Chronic Myeloid Leukemia From the PACE and OPTIC Trials

Author

Apperley, Jane, Kantarjian, Hagop, Deininger, Michael, Abruzzese, Elisabetta, Cortes, Jorge, Chuah, Charles, DeAngelo, Daniel J., DiPersio, John, Hochhaus, Andreas, Lipton, Jeffrey H., Nicolini, Frank, Pinilla-Ibarz, Javier, Rea, Delphine, Rosti, Gianantonio, Rousselot, Philippe, Mauro, Michael, Shah, Neil, Talpaz, Moshe, Vorog, Alexander, Ren, Xiaowei, and Jabbour, Elias

Published
2022
Full Text
View/download PDF

34. Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: the PEARL observational study

Author

Heiblig, Maël, Rea, Delphine, Chrétien, Marie-Lorraine, Charbonnier, Aude, Rousselot, Philippe, Coiteux, Valérie, Escoffre-Barbe, Martine, Dubruille, Viviane, Huguet, Françoise, Cayssials, Emilie, Hermet, Eric, Guerci-Bresler, Agnès, Amé, Shanti, Sackmann-Sala, Lucila, Roy, Lydia, Sobh, Mohamad, Morisset, Stéphane, Etienne, Gabriel, and Nicolini, Franck E.

Published
2018
Full Text
View/download PDF

35. Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial

Author

Cortes, Jorge E., Kim, Dong-Wook, Pinilla-Ibarz, Javier, le Coutre, Philipp D., Paquette, Ronald, Chuah, Charles, Nicolini, Franck E., Apperley, Jane F., Khoury, H. Jean, Talpaz, Moshe, DeAngelo, Daniel J., Abruzzese, Elisabetta, Rea, Delphine, Baccarani, Michele, Müller, Martin C., Gambacorti-Passerini, Carlo, Lustgarten, Stephanie, Rivera, Victor M., Haluska, Frank G., Guilhot, François, Deininger, Michael W., Hochhaus, Andreas, Hughes, Timothy P., Shah, Neil P., and Kantarjian, Hagop M.

Published
2018
Full Text
View/download PDF

36. ETNK1 mutations induce a mutator phenotype that can be reverted with phosphoethanolamine

Author

Fontana, Diletta, Mauri, Mario, Renso, Rossella, Docci, Mattia, Crespiatico, Ilaria, Røst, Lisa M., Jang, Mi, Niro, Antonio, D’Aliberti, Deborah, Massimino, Luca, Bertagna, Mayla, Zambrotta, Giovanni, Bossi, Mario, Citterio, Stefania, Crescenzi, Barbara, Fanelli, Francesca, Cassina, Valeria, Corti, Roberta, Salerno, Domenico, Nardo, Luca, Chinello, Clizia, Mantegazza, Francesco, Mecucci, Cristina, Magni, Fulvio, Cavaletti, Guido, Bruheim, Per, Rea, Delphine, Larsen, Steen, Gambacorti-Passerini, Carlo, and Piazza, Rocco

Published
2020
Full Text
View/download PDF

38. P668: CHRONIC MYELOID LEUKEMIA SURVEY ON UNMET NEEDS (CML SUN): BALANCING TOLERABILITY AND EFFICACY GOALS OF PATIENTS AND PHYSICIANS THROUGH SHARED TREATMENT DECISION-MAKING

Author

Lang, Fabian, primary, Pemberton-Whiteley, Zack, additional, Clements, Joannie, additional, Ruiz, Cristina, additional, Rea, Delphine, additional, Machado, Lisa, additional, Takahashi, Naoto, additional, Moon, Sung-Ho, additional, P Grigg, Andrew, additional, Borowczak, Cornelia, additional, Schuld, Peter, additional, Frank, Pauline, additional, Constantinescu, Cristina, additional, Boquimpani, Carla, additional, and Cortes, Jorge, additional

Published
2023
Full Text
View/download PDF

39. P670: EARLY CYTOGENETIC OR MOLECULAR LANDMARK RESPONSE TO PONATINIB TREATMENT PREDICTS OUTCOMES IN HEAVILY PRETREATED PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA IN PACE: 5-YEAR DATA

Author

Müller, Martin C., primary, Cortes, Jorge, additional, Chuah, Charles, additional, Deangelo, Daniel, additional, Deininger, Michael, additional, Guilhot, François, additional, Hughes, Timothy, additional, Emmanuel Nicolini, Franck, additional, Pinilla-Ibarz, Javier, additional, Rea, Delphine, additional, Rosti, Gianantonio, additional, Shah, Neil P., additional, Talpaz, Moshe, additional, Lu, Vickie, additional, Padukkavidana, Thihan, additional, and Kantarjian, Hagop, additional

Published
2023
Full Text
View/download PDF

40. P665: RAPID AND DEEP RESPONSES WITH ASCIMINIB IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) AFTER ≥2 PRIOR TYROSINE KINASE INHIBITORS (TKIS) IN THE PHASE 3 ASCEMBL STUDY

Author

Hughes, Timothy, primary, Rea, Delphine, additional, Boquimpani, Carla, additional, Minami, Yosuke, additional, Mauro, Michael, additional, Cortes, Jorge, additional, Apperley, Jane, additional, Garcia Gutierrez, Valentin, additional, Kapoor, Shruti, additional, Ktiouet-Dawson, Meryem, additional, Dhamal, Vishal, additional, and Hochhaus, Andreas, additional

Published
2023
Full Text
View/download PDF

42. Bone marrow mesenchymal stromal cell (MSC) gene profiling in chronic myeloid leukemia (CML) patients at diagnosis and in deep molecular response induced by tyrosine kinase inhibitors (TKIs)

Author

Aggoune, Djamel, Sorel, Nathalie, Bonnet, Marie-Laure, Goujon, Jean-Michel, Tarte, Karin, Hérault, Olivier, Domenech, Jorge, Réa, Delphine, Legros, Laurence, Johnson-Ansa, Hyacinthe, Rousselot, Philippe, Cayssials, Emilie, Guerci-Bresler, Agnès, Bennaceur-Griscelli, Annelise, Chomel, Jean-Claude, and Turhan, Ali G.

Published
2017
Full Text
View/download PDF

43. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study

Author

Rea, Delphine, Nicolini, Franck E., Tulliez, Michel, Guilhot, François, Guilhot, Joelle, Guerci-Bresler, Agnès, Gardembas, Martine, Coiteux, Valérie, Guillerm, Gaelle, Legros, Laurence, Etienne, Gabriel, Pignon, Jean-Michel, Villemagne, Bruno, Escoffre-Barbe, Martine, Ianotto, Jean-Christophe, Charbonnier, Aude, Johnson-Ansah, Hyacinthe, Noel, Marie-Pierre, Rousselot, Philippe, and Mahon, François-Xavier

Published
2017
Full Text
View/download PDF

45. Efficacy and safety of nilotinib in chronic myeloid leukaemia patients who failed to achieve a treatment‐free remission period after imatinib discontinuation: Results of the French Nilo post‐STIM study

Author

Dulucq, Stéphanie, primary, Rigal‐Huguet, Françoise, additional, Nicolini, Franck E., additional, Cony‐Makhoul, Pascale, additional, Escoffre‐Barbe, Martine, additional, Gardembas, Martine, additional, Legros, Laurence, additional, Rousselot, Philippe, additional, Liu, Jixing, additional, Rea, Delphine, additional, De Mas, Véronique, additional, Hayette, Sandrine, additional, Raynaud, Sophie, additional, Lacoste‐Roussillon, Caroline, additional, Robbesyn, Fanny, additional, Klein, Emilie, additional, Morisset, Stéphane, additional, Mahon, François‐Xavier, additional, and Etienne, Gabriel, additional

Published
2023
Full Text
View/download PDF

46. Data from Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients

Author

Nicolini, Franck Emmanuel, primary, Dulucq, Stéphanie, primary, Boureau, Lisa, primary, Cony-Makhoul, Pascale, primary, Charbonnier, Aude, primary, Escoffre-Barbe, Martine, primary, Rigal-Huguet, Françoise, primary, Coiteux, Valérie, primary, Varet, Bruno, primary, Dubruille, Viviane, primary, Lenain, Pascal, primary, Rousselot, Philippe, primary, Rea, Delphine, primary, Guerci-Bresler, Agnès, primary, Legros, Laurence, primary, Liu, Jixing, primary, Gardembas, Martine, primary, Ianotto, Jean-Christophe, primary, Turlure, Pascal, primary, Johnson-Ansah, Hyacinthe, primary, Martiniuc, Juliana, primary, Jardel, Henry, primary, Joly, Bertrand, primary, Zunic, Patricia, primary, Henni, Tawfiq, primary, Villemagne, Bruno, primary, Berger, Marc G., primary, Cayssials, Emilie, primary, Guilhot, François, primary, Larosa, Fabrice, primary, Guilhot, Joëlle, primary, Etienne, Gabriel, primary, and Mahon, François-Xavier, primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results